努力扩大阿片类药物使用障碍治疗的创新。
Innovations in efforts to expand treatment for opioid use disorder.
机构信息
Vermont Center on Behavior and Health, University of Vermont, Burlington, VT, United States of America; Department of Psychiatry, University of Vermont, Burlington, VT, United States of America; Department of Psychology, University of Vermont, Burlington, VT, United States of America.
出版信息
Prev Med. 2019 Nov;128:105818. doi: 10.1016/j.ypmed.2019.105818. Epub 2019 Aug 21.
Abstract
Fewer than 20% of Americans with opioid use disorder receive empirically-supported treatment. There is a critical need for innovative approaches to support expansion of evidence-based opioid treatment, particularly in rural geographic areas so impacted by the current opioid public health crisis. Doing so will require more diverse pathways into treatment, novel pharmacological tools, improved integration and efficiency among treatment modalities, and harm reduction when treatment is not available. In this invited commentary, we review exciting recent efforts to accomplish these aims as well as offer additional considerations for future clinical and research efforts to increase the availability of treatment for opioid use disorder.
摘要
接受循证治疗的阿片类药物使用障碍患者不足 20%。因此，迫切需要创新方法来支持扩大循证阿片类药物治疗，特别是在受当前阿片类药物公共卫生危机影响严重的农村地区。要做到这一点，就需要通过更多不同的途径进入治疗，使用新的药理学工具，提高治疗方式之间的整合和效率，并在无法提供治疗时减少伤害。在这篇特邀评论中，我们回顾了最近为实现这些目标而做出的令人兴奋的努力，并为未来增加阿片类药物使用障碍治疗的可及性的临床和研究工作提供了更多的考虑。
相似文献
1
Innovations in efforts to expand treatment for opioid use disorder.努力扩大阿片类药物使用障碍治疗的创新。
Prev Med. 2019 Nov;128:105818. doi: 10.1016/j.ypmed.2019.105818. Epub 2019 Aug 21.
2
TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.是时候重新审视美国在新冠疫情期间针对阿片类药物使用障碍药物治疗的不均衡政策了。
Addiction. 2020 Oct;115(10):1978-1979. doi: 10.1111/add.15143. Epub 2020 Jul 1.
3
Update on Barriers to Pharmacotherapy for Opioid Use Disorders.阿片类物质使用障碍药物治疗的障碍最新情况
Curr Psychiatry Rep. 2017 Jun;19(6):35. doi: 10.1007/s11920-017-0783-9.
4
Opioid Maintenance Therapy: A Review of Methadone, Buprenorphine, and Naltrexone Treatments for Opioid Use Disorder.阿片类药物维持治疗：美沙酮、丁丙诺啡和纳曲酮治疗阿片类药物使用障碍的综述。
Semin Neurol. 2024 Aug;44(4):441-451. doi: 10.1055/s-0044-1787571. Epub 2024 Jun 7.
5
Use and misuse of opioid replacement therapies: a Queensland study.阿片类药物替代疗法的使用和滥用：昆士兰研究。
Subst Use Misuse. 2012 Jan;47(1):78-85. doi: 10.3109/10826084.2011.629017.
6
Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.对谢勒等人（2014年）的评论：阿片类药物维持治疗中保留或不保留的开放性问题
Addiction. 2014 Jan;109(1):88-9. doi: 10.1111/add.12376.
7
A New Way Forward in the Emergency Department.急诊科的新发展方向。
J Med Toxicol. 2019 Oct;15(4):220-222. doi: 10.1007/s13181-019-00718-x. Epub 2019 Jul 5.
8
The case for a medication first approach to the treatment of opioid use disorder.采用药物优先治疗阿片类药物使用障碍。
Am J Drug Alcohol Abuse. 2019;45(4):333-340. doi: 10.1080/00952990.2019.1605372. Epub 2019 May 14.
9
Pharmacological treatment of opioid use disorder in pregnancy.妊娠期阿片类药物使用障碍的药物治疗。
Semin Perinatol. 2019 Apr;43(3):141-148. doi: 10.1053/j.semperi.2019.01.003. Epub 2019 Jan 21.
10
Medication-Based Treatment to Address Opioid Use Disorder.基于药物的阿片类物质使用障碍治疗方法。
JAMA. 2019 Jun 4;321(21):2071-2072. doi: 10.1001/jama.2019.5523.
引用本文的文献
1
Effects of the Communities that Heal (CTH) intervention on perceived opioid-related community stigma in the HEALing Communities Study: results of a multi-site, community-level, cluster-randomized trial.“治愈社区”（CTH）干预措施对“健康社区研究”中感知到的阿片类药物相关社区耻辱感的影响：一项多地点、社区层面、整群随机试验的结果
Lancet Reg Health Am. 2024 Mar 12;32:100710. doi: 10.1016/j.lana.2024.100710. eCollection 2024 Apr.
2
A scoping review of community-based post-opioid overdose intervention programs: implications of program structure and outcomes.基于社区的阿片类药物过量使用后干预项目的范围综述：项目结构与结果的影响
Health Justice. 2023 Jan 28;11(1):3. doi: 10.1186/s40352-022-00201-w.
3
Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C.扩大阿片类药物使用障碍治疗药物获取的法律：对 16 个州和华盛顿哥伦比亚特区的法律分析
Am J Drug Alcohol Abuse. 2022 Jul 4;48(4):492-503. doi: 10.1080/00952990.2022.2082301. Epub 2022 Jun 30.
4
Implications of Increased Access to Buprenorphine for Medical Providers in Rural Areas: A Review of the Literature and Future Directions.农村地区医疗服务提供者获取丁丙诺啡机会增加的影响：文献综述与未来方向
Cureus. 2021 Nov 24;13(11):e19870. doi: 10.7759/cureus.19870. eCollection 2021 Nov.
5
Opioid Treatment Deserts: Concept development and application in a US Midwestern urban county.阿片类药物治疗荒漠：概念的发展及其在美国中西部城市县的应用。
PLoS One. 2021 May 12;16(5):e0250324. doi: 10.1371/journal.pone.0250324. eCollection 2021.
6
The next wave? Mental health comorbidities and patients with substance use disorders in under-resourced and rural areas.下一波浪潮？资源匮乏和农村地区物质使用障碍患者的精神健康共病问题。
J Subst Abuse Treat. 2021 Feb;121:108189. doi: 10.1016/j.jsat.2020.108189. Epub 2020 Nov 4.
7
Comparison of Rural vs Urban Direct-to-Physician Commercial Promotion of Medications for Treating Opioid Use Disorder.农村与城市直接向医生推广治疗阿片类药物使用障碍药物的比较。
JAMA Netw Open. 2019 Dec 2;2(12):e1916520. doi: 10.1001/jamanetworkopen.2019.16520.
8
Behavior change, health, and health disparities 2019: Opioids, tobacco, and treatment adherence.行为改变、健康和健康差异 2019：阿片类药物、烟草和治疗依从性。
Prev Med. 2019 Nov;128:105887. doi: 10.1016/j.ypmed.2019.105887. Epub 2019 Nov 9.
本文引用的文献
1
Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.通过移动治疗向涉及司法的个人扩大低门槛丁丙诺啡治疗：解决关键护理差距。
J Subst Abuse Treat. 2019 Aug;103:1-8. doi: 10.1016/j.jsat.2019.05.002. Epub 2019 May 9.
2
Commentary on Jones & McCance-Katze (2019): Buprenorphine and the glass half full-why can't we prescribe more of it, and will nurse practitioners and physician assistants fulfill a chronic unmet need?
Addiction. 2019 Mar;114(3):483-484. doi: 10.1111/add.14545. Epub 2019 Jan 21.
3
Assessment of medication for opioid use disorder as delivered within the Vermont hub and spoke system.评估佛蒙特州中心辐射系统中提供的阿片类药物使用障碍治疗药物。
J Subst Abuse Treat. 2019 Feb;97:84-90. doi: 10.1016/j.jsat.2018.11.003. Epub 2018 Nov 19.
4
Expanding access to buprenorphine treatment in rural areas with the use of telemedicine.利用远程医疗扩大农村地区丁丙诺啡治疗的可及性。
Am J Addict. 2018 Dec;27(8):612-617. doi: 10.1111/ajad.12805. Epub 2018 Sep 28.
5
Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms.延迟接受综合治疗期间的丁丙诺啡临时治疗：精神症状的变化
Exp Clin Psychopharmacol. 2018 Aug;26(4):403-409. doi: 10.1037/pha0000199. Epub 2018 Jun 25.
6
Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.每周和每月皮下注射丁丙诺啡储库制剂与每日舌下含服丁丙诺啡-纳洛酮治疗阿片类药物使用障碍的随机临床试验。
JAMA Intern Med. 2018 Jun 1;178(6):764-773. doi: 10.1001/jamainternmed.2018.1052.
7
Gaps in the Substance Use Disorder Treatment Referral Process: Provider Perceptions.物质使用障碍治疗转介过程中的差距：提供者的看法。
J Addict Med. 2018 Jul/Aug;12(4):273-277. doi: 10.1097/ADM.0000000000000400.
8
Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program.描述和结果的丁丙诺啡维持治疗计划整合内预防点费城,一个城市注射器交换计划。
Subst Abus. 2018;39(2):167-172. doi: 10.1080/08897077.2018.1443541. Epub 2018 May 4.
9
The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting.远程医疗提供的阿片类激动剂疗法在有监督的临床环境中的有效性。
Drug Alcohol Depend. 2017 Jul 1;176:133-138. doi: 10.1016/j.drugalcdep.2017.01.048. Epub 2017 May 17.
10
Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact.佛蒙特州阿片类药物使用障碍的中心辐射式护理模式：发展、实施与影响
J Addict Med. 2017 Jul/Aug;11(4):286-292. doi: 10.1097/ADM.0000000000000310.
Zotero 插件